23ME610 is under clinical development by 23AndMe and currently in Phase II for Fallopian Tube Cancer. According to GlobalData, Phase II drugs for Fallopian Tube Cancer have a 42% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how 23ME610’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
23ME610 is under development for the treatment of locally advanced or metastatic solid malignancies including clear cell renal cell carcinoma, epithelial ovarian, fallopian tube, primary peritoneal carcinoma, neuroendocrine cancers including small cell lung cancer and microsatellite instability-high (MSI-H) or tumor mutational burden-high (TMB-H) cancers. The therapeutic candidate comprises of a fully humanized IgG1 antibody which acts by targeting CD200R1. It is administered through intravenous route.
23andMe, formerly VG Acquisition Corp is a blank check/SPAC (special purpose acquisition company). It was formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The company is headquartered in New York, the US.
For a complete picture of 23ME610’s drug-specific PTSR and LoA scores, buy the report here.